The Medicines Company (NASDAQ:MDCO) insider Fredric N. Eshelman purchased 200,000 shares of the stock in a transaction dated Friday, December 8th. The stock was acquired at an average cost of $26.56 per share, for a total transaction of $5,312,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

The Medicines Company (NASDAQ MDCO) traded down $0.21 during trading on Monday, reaching $26.00. 1,575,722 shares of the company were exchanged, compared to its average volume of 1,430,273. The company has a debt-to-equity ratio of 3.42, a quick ratio of 1.79 and a current ratio of 2.31. The Medicines Company has a twelve month low of $25.40 and a twelve month high of $55.95.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.37) by $0.95. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The Medicines’s revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.64) EPS. research analysts expect that The Medicines Company will post -8.86 EPS for the current year.

MDCO has been the topic of several research reports. Chardan Capital reissued a “buy” rating and issued a $85.00 price target (up previously from $80.00) on shares of The Medicines in a research report on Tuesday, August 29th. Zacks Investment Research lowered shares of The Medicines from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 10th. Guggenheim initiated coverage on shares of The Medicines in a research report on Monday, October 23rd. They issued a “buy” rating and a $45.00 price target on the stock. Jefferies Group reissued a “buy” rating and issued a $54.00 price target on shares of The Medicines in a research report on Thursday, September 14th. Finally, Oppenheimer set a $50.00 price target on shares of The Medicines and gave the company a “hold” rating in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The Medicines currently has an average rating of “Buy” and a consensus price target of $53.67.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in The Medicines by 1.1% during the 2nd quarter. FMR LLC now owns 10,825,038 shares of the company’s stock worth $411,460,000 after acquiring an additional 117,982 shares during the period. Iridian Asset Management LLC CT increased its holdings in shares of The Medicines by 21.7% in the 2nd quarter. Iridian Asset Management LLC CT now owns 3,677,746 shares of the company’s stock worth $139,791,000 after buying an additional 655,065 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of The Medicines by 21.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,476,778 shares of the company’s stock worth $91,740,000 after buying an additional 445,419 shares during the last quarter. State Street Corp increased its holdings in shares of The Medicines by 9.0% in the 2nd quarter. State Street Corp now owns 2,220,199 shares of the company’s stock worth $84,391,000 after buying an additional 183,086 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of The Medicines by 24.1% in the 2nd quarter. Franklin Resources Inc. now owns 1,765,169 shares of the company’s stock worth $67,093,000 after buying an additional 343,160 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/11/the-medicines-company-mdco-insider-fredric-n-eshelman-buys-200000-shares.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.